文献速递脑血管病

依洛尤单抗联合他汀对稳定动脉粥样硬化高危患者卒中预防的预设分析

Stroke Prevention With the PCSK9 (Proprotein Convertase Subtilisin-Kexin Type 9) Inhibitor Evolocumab Added to Statin in High-Risk Patients With Stable Atherosclerosis.
PubMed 文献 · Stroke · 2020-04-21

FOURIER试验预设分析纳入27 564例稳定动脉粥样硬化患者,中位随访2.2年,依洛尤单抗在他汀基础上显著降低所有卒中(HR 0.79)和缺血性卒中(HR 0.75),未增加出血性卒中风险,既往缺血性卒中亚组结果一致。

要点

  • 依洛尤单抗显著降低所有卒中和缺血性卒中风险,不增加出血性卒中。
  • 既往缺血性卒中患者亚组获益与总体人群一致。
  • 卒中的独立预测因素包括既往缺血性卒中、糖尿病、CRP升高、心衰史等。

核心结论

  • 在他汀基础上加用依洛尤单抗可降低稳定动脉粥样硬化患者的缺血性卒中和心血管事件,包括既往缺血性卒中患者。

研究设计与样本

  • FOURIER为随机双盲试验,比较依洛尤单抗与安慰剂,纳入已确诊动脉粥样硬化、额外危险因素且他汀治疗下LDL胆固醇≥1.8或非HDL≥2.6 mmol/L的患者,中位随访2.2年。
  • 共纳入27 564例患者,其中5337例(19%)有既往缺血性卒中。

主要发现

  • 469例(1.7%)发生503次卒中,其中421次(84%)为缺血性卒中。
  • 依洛尤单抗显著降低所有卒中(1.5% vs 1.9%;HR 0.79,95%CI 0.66-0.95;P=0.01)和缺血性卒中(1.2% vs 1.6%;HR 0.75,95%CI 0.62-0.92;P=0.005)。
  • 出血性卒中无差异(0.21% vs 0.18%;HR 1.16,95%CI 0.68-1.98;P=0.59)。
  • 既往缺血性卒中亚组中,心血管复合终点HR 0.85(95%CI 0.72-1.00),所有卒中HR 0.90(95%CI 0.68-1.19),缺血性卒中HR 0.92(95%CI 0.68-1.25),交互P分别为0.91、0.22、0.09。
  • 卒中的独立预测因素包括既往缺血性卒中、糖尿病、CRP升高、心衰史、高龄、非白种族、外周动脉疾病和肾功能不全。

临床怎么用

  • 对已确诊动脉粥样硬化且他汀治疗下LDL胆固醇≥1.8 mmol/L的高危患者,可考虑加用依洛尤单抗以降低缺血性卒中风险。
  • 既往有缺血性卒中的患者使用依洛尤单抗的获益与总体人群一致,不增加出血性卒中风险。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Background and Purpose- The PCSK9 (proprotein convertase subtilisin-kexin type 9) monoclonal antibody evolocumab lowered LDL (low-density lipoprotein) cholesterol by 59% to 0.8 (0.5-1.2) mmol/L and significantly reduced major vascular events in the FOURIER trial (Further Cardiovascular Outcomes Research with PCSK9 Inhibition in Subjects with Elevated Risk). Herein, we report the results of a prespecified analysis of cerebrovascular events in the overall trial population and in patients stratified by prior stroke. Methods- FOURIER was a randomized, double-blind trial comparing evolocumab versus placebo in patients with established atherosclerosis, additional risk factors, and LDL cholesterol levels ≥1.8 (or non-HDL [high-density lipoprotein] ≥2.6 mmol/L) on statin therapy. The median follow-up was 2.2 years. We analyzed the efficacy of evolocumab to reduce overall stroke and stroke subtypes, as well as the primary cardiovascular composite end point by subgroups according to a history of stroke. Results- Among the 27 564 patients, 469 (1.7%) experienced a total of 503 strokes of which 421 (84%) were ischemic. Prior ischemic stroke, diabetes mellitus, elevated CRP (C-reactive protein), history of heart failure, older age, nonwhite race, peripheral arterial disease, and renal insufficiency were independent predictors of stroke. Evolocumab significantly reduced all stroke (1.5% versus 1.9%; hazard ratio, 0.79 [95% CI, 0.66-0.95]; P=0.01) and ischemic stroke (1.2% versus 1.6%; hazard ratio, 0.75 [95% CI, 0.62-0.92]; P=0.005), with no difference in hemorrhagic stroke (0.21% versus 0.18%; hazard ratio, 1.16 [95% CI, 0.68-1.98]; P=0.59). These findings were consistent across subgroups, including among the 5337 patients (19%) with prior ischemic stroke in whom the hazard ratios (95% CIs) were 0.85 (0.72-1.00) for the cardiovascular composite, 0.90 (0.68-1.19) for all stroke, and 0.92 (0.68-1.25) for ischemic stroke (P interactions, 0.91, 0.22, and 0.09, respectively, compared with patients without a prior ischemic stroke). Conclusions- Inhibition of PCSK9 with evolocumab added to statin in patients with established atherosclerosis reduced ischemic stroke and cardiovascular events in the total population and in key subgroups, including those with prior ischemic stroke. Registration- URL: https://www.clinicaltrials.gov; Unique identifier: NCT01764633.

来源:Stroke,查看原文。版权归原作者所有。

引用

  1. Giugliano RP, Pedersen TR, Saver JL, et al. Stroke Prevention With the PCSK9 (Proprotein Convertase Subtilisin-Kexin Type 9) Inhibitor Evolocumab Added to Statin in High-Risk Patients With Stable Atherosclerosis. Stroke. 2020. PMID: 32312223. doi:10.1161/STROKEAHA.119.027759

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。